The aim of this study was to investigate succinate dehydrogenase (SDH) expression in breast cancer according to breast cancer molecular subtype using immunohistochemistry and to assess the clinical implications of SDH expression. Immunohistochemical staining for ER, PR, HER-2, Ki-67, HIF-1α, SDHA, and SDHB was performed on tissue microarrays of 721 breast cancers. According to the immunohistochemistry results for ER, PR, HER-2, and Ki-67 and fluorescence in situ hybridization (FISH) results for HER-2, breast cancer molecular subtypes were classified into luminal A, luminal B, HER-2, and triple-negative breast cancer (TNBC). HER-2 subtype breast cancers most frequently showed high-level expression of SDHA in tumor cells, while the luminal A subtype most frequently showed low or negative expression of SDHA in tumor cells (P = 0.032). Stromal SDHB expression rate was highest in HER-2 subtype and lowest in TNBC (P < 0.001). SDHA-negative breast cancers were associated with younger age at diagnosis (P = 0.012), and SDHB-negative breast cancers with lower histologic grade (P = 0.044) and lower Ki-67 labeling index (LI) (P = 0.046). Tumor phenotypes according to the SDH status were SDHA(+)/SDHB(+) > SDHA(-)/SDHB (-) > SDHA(-)/SDHB(+) > SDHA(+)/SDHB(-) in order of frequency. The stromal phenotypes were SDHA(-)/SDHB (-) > SDHA(+)/SDHB(+) > SDHA(-)/SDHB(+) > SDHA(+)/SDHB(-). In conclusion, loss of SDHA or SDHB expression was observed in about 3% of breast cancers in this study. Low SDH expression status in breast tumor cells was associated with younger age at diagnosis and low-grade histology.
Introduction
Succinate dehydrogenase (SDH) (succinate-coenzyme Q reductase, respiratory Complex II) catalyzes the oxidation of succinate to fumarate with the reduction of ubiquinone to ubiquinol. Through the coupling of these two reactions in the inner mitochondrial membrane, SDH links glucose oxidation in the TCA cycle with ATP production in the mitochondria (Cardaci & Ciriolo 2012; King et al. 2006; Barletta & Hornick 2012; Van Nederveen et al. 2009 ). SDH is composed of four subunits; SDHA, SDHB, SDHC and SDHD. The first two are hydrophilic proteins protruding into the mitochondrial matrix, and the second two are hydrophobic proteins that anchor the catalytic core into the inner mitochondrial membrane (Cardaci & Ciriolo 2012; King et al. 2006; Barletta & Hornick 2012; Van Nederveen et al. 2009 ).
Germline loss-of-function SDH mutations are associated with several tumors such as pheochromocytoma and paraganglioma, gastrointestinal stromal tumor (GIST), and renal cell carcinoma (Hensen & Bayley 2011; Kantorovich et al. 2010; Anderson et al. 2004; Astuti et al. 2001; Miettinen et al. 2011; Badve et al. 2011; Ricketts et al. 2008) . Among these, GIST and renal cell carcinoma are reported to display histologic features that distinguish SDH-deficient tumors (Miettinen et al. 2011) . Although SDH germline mutation may be accurately evaluated by gene sequencing, a few recent studies have shown very high sensitivity for immunohistochemical detection of SDH mutation in GIST, pheochromocytoma, and paraganglioma (Van Nederveen et al. 2009; Gill et al. 2010a; Miettinen et al. 2013; Janeway et al. 2011 ).
To date, few studies have investigated SDH expression in breast cancer. We investigated SDH expression status according to breast cancer molecular subtype using immunohistochemical methods and assessed the clinical implications of SDH expression in breast cancer.
Materials and methods

Patient selection
Patients who were diagnosed with invasive ductal carcinoma, not otherwise specified and underwent surgical excision at Severance Hospital between January 2002 and December 2005 were included in the study. Patients who received preoperative hormonal therapy or neoadjuvant chemotherapy were excluded. All hematoxylin and eosin (H&E)-stained slides for each case were retrospectively reviewed by breast pathologists (Koo JS). The histological grade was assessed using the Nottingham grading system. (Elston & Ellis 1991) The clinicopathologic parameters evaluated for each breast cancer included patient age at initial diagnosis, lymph node metastasis, tumor recurrence, distant metastasis, and patient survival. The Institutional Review Board of Yonsei University Severance Hospital approved this study.
Tissue microarray
On H&E-stained slides of tumors, a representative area was selected and a corresponding spot was marked on the surface of the paraffin block. Using a biopsy needle, the selected area was punched out and a 3-mm core of tumor tissue was placed onto a 6 × 5 recipient block. Two tissue cores were extracted from each sample to minimize bias. Each tissue core was assigned a unique microarray location number that was linked to clinicopathologic data in a database.
Immunohistochemistry
All immunohistochemical staining was performed on formalin-fixed, paraffin-embedded tissue sections using antibodies as indicated (Table 1) . Briefly, 5-μm-thick sections were obtained with a microtome, transferred onto adhesive slides, and dried at 62°C for 30 min. After incubation with primary antibodies, immunodetection was performed with biotinylated antimouse immunoglobulin, followed by peroxidase-labeled streptavidin using a labeled streptavidin biotin kit with 3,3′-diaminobenzidine chromogen as substrate. The primary antibody incubation step was omitted in the negative control. Slides were counterstained with Harris hematoxylin.
Interpretation of immunohistochemical staining
All immunohistochemical markers were assessed by light microscopy. Parameters such as ER, PR, and HER-2 status were obtained from patients' pathologic reports. A cut-off value of 1% or more positively stained nuclei was used to define ER and PR positivity (Hammond et al. 2010) . HER-2 staining was analyzed according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines using the following categories: 0, no immunostaining; 1+, weak incomplete membranous staining, less than 10% of tumor cells; 2+, complete membranous staining, either uniform or weak in at least 10% of tumor cells; and 3+, uniform intense membranous staining in at least 30% of tumor cells (Wolff AC, et al. 2007 ). HER-2 immunostaining was recorded as positive when strong (3+) membranous staining was observed, whereas staining categories 0 to 1+ were recorded as negative. Samples showing 2+ HER-2 expression were evaluated for HER-2 amplification by fluorescence in situ hybridization (FISH).
Immunohistochemical staining for SDHA and SDHB showed cytoplasmic expression with a granular pattern. Complete loss of expression was considered negative, while cytoplasmic expression in less than 50% of tumor cells was considered low expression, and cytoplasmic expression in more than 50% of tumor cells was considered high expression (Figure 1 ). HIF-1α was considered positive when more than 10% of tumor cells showed strong cytoplasmic or nuclear expression.
Fish analysis
FISH was performed using a PathVysion HER-2 DNA Probe Kit (Vysis, Downers Grove, IL, USA) according to the manufacturer's instructions. Invasive tumors were first examined on hematoxylin-eosin-stained slides to confirm histology. HER-2 gene copy number on the slides was evaluated using an epifluorescence microscope (Olympus, Tokyo, Japan) according to the ASCO/CAP guidelines (Wolff AC, et al. 2007) . At least 60 tumor cell nuclei in three separate regions were investigated for HER-2 and chromosome 17 signals. An absolute HER-2 gene copy number lower than 4 or an HER-2 gene/chromosome 17 copy number ratio (HER-2/Chr17 ratio) less than 1.8 was considered HER-2-negative. An absolute HER-2 copy number between 4 and 6 or an HER-2/Chr17 ratio between 1.8 and 2.2 was considered HER-2-equivocal. An absolute HER-2 copy number greater than 6 or an HER-2/Chr17 ratio higher than 2.2 was considered HER-2-positive. 
Statistical analysis
Data were analyzed using SPSS for Windows, Version 12.0 (SPSS Inc., Chicago, IL, USA). Student's t and Fisher's exact tests were used to evaluate continuous and categorical variables, respectively. The significance level was set at 0.05. The time to tumor recurrence and overall survival were evaluated by Kaplan-Meier and log-rank statistics. Multivariate regression analysis was performed using the Cox proportional hazards model.
Results
Patients' characteristics
Clinicopathological characteristics according to breast cancer molecular subtype are shown in Table 2 . Molecular subtypes among these 721 breast cancers included 302 luminal A (41.9%), 168 luminal B (23.3%), 69 HER-2 type (9.6%), and 182 TNBC (25.2%). TNBC showed higher histologic grade (P < 0.001), higher T stage (P = 0.007), and higher Ki-67 LI (P < 0.001) than other molecular subtypes. The HER-2 subtype was positively associated with age (P = 0.005) and with tumor recurrence and death (P = 0.001).
HIF-1α and sdh status according to molecular subtype of breast cancer HIF-1α, SDHA, and SDHB expression according to breast cancer subtype are shown in Table 3 and Figure 2 . Only 24 (3.3%) and 4 (0.6%) of 721 breast cancers displayed HIF-1α expression in the nucleus and cytoplasm, respectively. The HER-2 tumor subtype showed the highest frequency of high SDHA expression, and the luminal A subtype most frequently showed low or negative SDHA expression (P = 0.032). Stromal SDHB expression frequency was highest in the HER2 subtype and lowest in TNBC (P < 0.001). Stromal SDHA expression was detected most frequently in the HER-2 subtype, although the correlation was not significant (P = 0.063). Nuclear HIF-1α expression and SDHA/SDHB expression did not correlate significantly (Table 4) ; however, SDHA and SDHB expression were correlated significantly (r = 0.895, P < 0.001, Figure 3 ).
Clinicopathologic characteristics of breast cancer with SDHA and/or SDHB negativity
Clinicopathologic characteristics of breast cancers were compared between the SDHA/SDHB positive and negative breast cancers (Table 5) . Tumor negativity for SDHA correlated with earlier age at diagnosis of breast cancer (P = 0.012) and with lower histologic grade (P = 0.062). SDHB-negative breast cancer correlated with lower histologic grade (P = 0.044) and lower Ki-67 LI (P = 0.046). There was no correlation between the expression status of SDH and that of nuclear HIF-1α (Table 4) .
Correlations between clinicopathologic parameters and expression of Hif-1α and SDH
Correlation analysis between HIF-1α and SDH expression and clinicopathologic factors revealed an association of nuclear HIF-1α expression with PR negativity (P = 0.011), and of low or negative SDHA expression in the tumor with ER positivity (P = 0.044), HER-2 negativity (P = 0.021), and higher T stage (P = 0.031). Low or negative SDHB expression in the tumor was associated with higher T stage (P = 0.011). Stromal SDHB negativity was associated with HER-2 negativity (P < 0.001, Table 6 ).
Clnicopathologic features according the phenotype of SDH expression in breast cancer
The SDHA/SDHB expression phenotypes in these 712 breast tumors were, in order of frequency, SDHA (+)/SDHB(+) > SDHA(-)/SDHB(-) > SDHA(-)/SDHB(+) > SDHA(+)/SDHB(-). The stroma phenotypes were SDHA (-)/SDHB(-) > SDHA(+)/SDHB(+) > SDHA(-)/SDHB(+) > SDHA(+)/SDHB(-) ( Table 7) . SDHA(+)/SDHB(+) tumors tended to have higher histologic grades than SDHA(+)/SDHB(-) and SDHA(-)/SDHB (-) tumors (P = 0.038). Stromal SDHA(-)/SDHB(+) tumors showed the highest frequency of HER-2 positivity, while stromal SDHA(+)/SDHB(-) tumors showed lowest HER-2 positivity (P = 0.001). Stromal SDHA/SDHB phenotype differed significantly between the molecular subtypes, SDHA (+)/SDHB(+) being most frequent in Luminal A and least in TNBC tumors. The SDHA(+)/SDHB(-) phenotype was most frequent in TNBC and least frequent in HER-2 subtype tumors; SDHA(-)/SDHB(+) was most frequent in Luminal B and least in TNBC; and SDHA(−)/SDHB(-) was most frequent in the Luminal A and least in the HER-2 subtype (P < 0.001).
Prognostic significance of HIF-1α and SDH expression status
In univariate analysis, neither HIF-1α nor SDH expression was significantly related to patient outcome (Table 8) . In multivariate Cox analysis (Table 9) , factors negatively associated with DFS were T stage (Hazard ratio: 2.535, 95% CI: 1.376 − 4.670, P = 0.003), lymph node metastasis (Hazard ratio: 2.257, 95% CI: 1.335 − 3.816, P = 0.002), and high histologic grade (Hazard ratio: 1.685, 95% CI: 1.013 − 2.804, P = 0.045). Factors negatively associated with OS were T stage (Hazard ratio: 2.218, 95% CI: 1.229 − 4.001, P = 0.008), lymph node metastasis (Hazard ratio: 1.831, 95% CI: 1.076 − 3.115, P = 0.026), high tumor expression of SDHA (Hazard ratio: 4.157, 95% CI: 1.657 − 10.432, P = 0.002), and low SDHB expression (Hazard ratio: 3.223, 95% CI: 1.295 − 8.025, P = 0.012). Gill et al. 2010b; Gill et al. 2011a) , and renal cell carcinomas (Gill et al. 2011b) . Until recently, the accurate detection of SDH mutation depended primarily on direct sequencing and western blotting, methods that a clinical laboratory may find too costly and timeconsuming. However, in a study of paraganglioma and pheochromocytoma, Van Nederveen et al. demonstrated the high sensitivity of immunohistochemical Using similar methods in the present study, we found that 23 of 721 breast cancer patients (3.19%) had SDHA mutation (SDHA-/SDHB-expression) and one patient (0.1%) had an SDHB mutation (SHDA+/SDHB-expression; Table 7 ). As few previous studies have evaluated SDH mutation in breast cancer, these findings provide a starting point for future investigations. However, a Negative n = 697 (%) Positive n = 24 (%) P-value Negative n = 717 (%) Positive n = 4 (%) P-value previous study reported that SDH germline mutations or variants occur in some patients with Cowden syndrome (CS) who do not present the expected PTEN mutation. Compared with patients positive for germline PTEN mutation, these CS/CS-like individuals develop cancers of the breast, thyroid, and kidney at higher frequencies (Ni et al. 2008) . Therefore, some breast cancer patients may be expected to have SDH mutations. Findings in this study may be limited in that the sensitivity of immunohistochemistry in detecting SDH mutation as compared to direct sequencing has not been tested in breast cancer. We have assumed a degree of reliability in breast cancer similar to that of the detection of SDH germline mutations in paraganglioma and pheochromocytoma (Van Nederveen et al. 2009 ). To confirm SDH mutation, loss of SDH expression should be tested throughout the entire tumor (Barletta & Hornick 2012) , whereas in this study, immunohistochemistry was performed on the tissue microarray only.
In previous studies of pheochromocytoma and GIST, SDH-deficient tumors showed complete loss of cytoplasmic granular expression (Miettinen et al. 2011; GimenezRoqueplo et al. 2003) . Even though weak, focal or diffuse cytoplasmic staining was observed in a very few tumor cells of SDH-deficient tumor, this finding may be considered negative, because it is clearly distinguishable from the strong speckled expression pattern in surrounding non-neoplastic elements. However, stromal cells did not express SDHA and SDHB in most breast cancers in this study, which made it impossible to compare the staining intensity between tumor cells and internal normal controls (stromal cells). Therefore, expression in tumor cells was interpreted at three grade levels according to the proportion of cells stained: grade (1), 
